Background: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is widely recommended for the treatment of aggressive B-cell lymphomas. However, there is very little information regarding the management of elderly patients.
With life expectancy generally increasing, the incidence of many malignancies, including aggressive lymphoma, continues to rise. Non-Hodgkin's lymphoma (NHL) is the fifth most common cancer in the United States with a rapidly rising ageadjusted incidence. The incidence is age dependent and increases markedly with age. In the age of 80-84 years, 112 cases of NHL per 100 000 persons were reported [1] . Thus, with the general increase of elderly people, a further increase of absolute numbers of NHL patients can be expected, especially in very elderly patients. As the prognosis is significantly worse in this population as compared with younger patients, the selection of appropriate treatment modalities is a real challenge [2] . Although combined immunochemotherapy with the anti-CD20 monoclonal antibody rituximab and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like therapies have become the worldwide accepted standard therapy in aggressive B-cell lymphoma even in elderly patients with a good performance status and little comorbidity, there is hardly any data using this treatment option in patients who are 80 years or older [1] [2] [3] . Almost all trials in elderly patients with aggressive lymphoma focused on the age-group of 60-80 years [1, 4, 5] . However, the frequency of comorbidities disqualifying patients from CHOP-like treatment is high in patients older than of 80 years. Ineligibility for CHOP-like treatment is associated with a shorter survival [6] , especially as the survival in older patients without concomitant disease is comparable with that of younger patients [7] . Therefore, alternative effective treatment modalities with less toxicity are required.
Several years ago, we published the results of a phase II study with bendamustine in patients with relapsed or refractory aggressive B-cell lymphomas, who did not have a curative treatment option. We observed an overall response rate (ORR) of 44% in 18 patients with a few long-lasting complete remissions even in patients with refractory disease [8] . As these results proved efficacy of bendamustine in aggressive lymphoma and as the drug was very well tolerated, we felt encouraged to design the present trial with bendamustine and rituximab for first-line treatment in patients 80 years or older with aggressive B-cell lymphomas, who did not qualify for R-CHOP.
Bendamustine, first synthesized back in the 1960s in the former German Democratic Republic, consists of a nitrogen mustard moiety bound to a purine-like ring [9] . Several preclinical and clinical findings suggested that the activity profile and the mechanism of action of the drug significantly differ from classical alkylators. In vitro studies showed rapid DNA cross-linking and strand breaks [10] . Furthermore, inhibition of mitotic checkpoints [11] by bendamustine and synergism between the drug and rituximab [12] have been shown in in vitro studies. Recently, thorough comparative examinations on the mechanism of action revealed the unique effects of bendamustine and major differences in cytotoxic effects in vitro [11] . Consequently, a lack of crossresistance to other DNA-damaging cytotoxic drugs could be detected.
Bendamustine has shown a broad clinical activity in the treatment of numerous hematological and solid malignancies [13] . Based on the findings of several phase I and II trials in NHL and chronic lymphocytic leukemia, several randomized trials were initiated to compare bendamustine with standard therapies [9, 14, 15] . The combination of bendamustine with rituximab has been studied in several trials in low-grade lymphomas. This combination of bendamustine and rituximab has been demonstrated to be highly active with low toxicity, as reported in previously [16] [17] [18] .
We present the first study including bendamustine in a firstline regimen for treatment of patients with aggressive B-cell lymphomas, in combination with rituximab. The purpose of the study was to determine whether this combination was suitable for patients with aggressive B-cell lymphomas, who did not qualify for combinations of rituximab with CHOP-like regimens.
patients and methods patients
This was a phase II open-label study that aimed to investigate the feasibility, toxicity, and activity of bendamustine in combination with rituximab in newly diagnosed elderly patients with aggressive B-cell lymphomas. Fourteen patients were enrolled between April 2004 and June 2006. Patients were required to have been diagnosed with a high-grade B-cell lymphoma of any stage or with a mantle cell lymphoma stage III or IV, without previous preceding therapy. Patients 80 years or older who were not eligible for R-CHOP were included. The treatment decision on eligibility for R-CHOP was left to the physician's discretion. Patients younger than 80 years with contraindications to R-CHOP could also be included. Patients with relapsed disease or those in a palliative setting or a life expectancy shorter than 3 months, those with major organ dysfunction or organspecific laboratory parameters exceeding three times the normal values, those with heart failure (ejection fraction <35%), those with severe psychiatric diseases, and those with severe acute infections were excluded from the study.
The study was carried out in accordance with the ethical principles laid down in the Declaration of Helsinki and the study design was approved by the local ethics committees of the participating centers. All patients gave written informed consent.
treatment
Rituximab was administered at a dose of 375 mg/m 2 on day 1 of each treatment cycle (the first 50 mg over 1 h, 100 mg during the second hour, 200 mg during the third hour, and 300 mg/h thereafter). According to our previous study in aggressive lymphomas [7] , the dose of bendamustine was 120 mg/m 2 on 2 consecutive days (days 2 and 3 of each cycle) and cycles were administered at 21-day intervals.
Patients with stage I/II disease received four cycles of bendamustine and rituximab as described above, followed by involved-field irradiation. Patients with stage III/IV disease received six cycles of bendamustine and rituximab followed by two consolidating administrations of rituximab, given also at 3-weekly intervals.
Treatment was postponed if leukocyte counts were <3.5/nl or thrombocyte counts were <100/nl at the end of the previous treatment cycle. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was not recommended by the protocol because in our previous study, grade 3 and 4 neutropenia and infections were observed in <10% of all treatment cycles [8] .
Physical examinations and full laboratory and diagnostic evaluations were carried out before each treatment cycle. Blood counts and biochemical profile were assessed twice weekly during treatment. Interim staging was carried out after three and six treatment cycles in patients with stage III or IV, and after two and four cycles in patients with stage I or II disease, respectively. This staging involved computed tomography (CT) scans of the neck, chest, and abdomen (including the pelvis), and repeating the diagnostic tests that had yielded pathological results at initial staging (e.g. bone marrow biopsy). Follow-up examinations after consolidating rituximab in patients with stage III or IV or after irradiation in patients with stage I or II disease, including CT scans and all diagnostic procedures that had revealed lymphoma involvement, were carried out every 3 months for the first 2 years after the end of treatment, and then every 6 months until 5 years after finishing treatment.
response evaluation
Responses were evaluated according to the International Workshop Criteria for NHLs [19] .
end points and their assessment
The primary end points were feasibility and assessment of toxicity and efficacy. Efficacy was defined as the rates of complete and partial responses. Secondary end points were the assessment of progression-free survival (PFS) and overall survival (OS). PFS was defined as time from first day of rituximab administration until disease progression or death of any cause. OS was calculated from the day of administration of the first dose of rituximab to death; deaths for any reason were included. Toxic effects were assessed according to World Health Organisation grading. Estimates of PFS and OS were calculated using the Kaplan-Meier method.
statistical analysis
The initially planned patient population was 30 patients. An interim analysis was planned after 15 patients. In case of a response rate of 60% or more and acceptable toxicity, recruitment was to be expanded to the full study size of 30 patients. However, due to slow recruitment of patients, the study was stopped after the described 14 patients.
results patient characteristics
Patient characteristics are summarized in Table 1 . Overall, 14 patients, 9 men and 5 women, with a median age of 85 years (range 80-95 years) were enrolled. Eight patients had stage I or original article Annals of Oncology II and six patients stage III or IV disease. A low or intermediate-low risk according to age-adjusted international prognostic index (aaIPI) was assigned to eight patients and an intermediate-high risk to six patients. Eleven of the 14 patients had diffuse large B-cell lymphomas, one an unclassified aggressive B-cell lymphoma, one a mantle cell lymphoma, and one a follicular lymphoma of grade III. The majority of the patients were judged by their physicians not to be eligible for R-CHOP because of comorbidities and moderately reduced performance status. However, four patients refused treatment with R-CHOP.
efficacy Overall, 13 of the 14 patients were assessable for response. The ORR was 69% [95% confidence interval (CI) 44% to 94%], with seven complete response (CR) (54%; 95% CI 26% to 81%) and two partial response (15%; 95% CI 24% to 34%). Progressive disease was documented in four patients (31%; 95% CI 6% to 56%; data not shown). Responses were not affected by consolidation treatment with radiation or rituximab.
In the patient who was not assessable for response, treatment was changed to bendamustine monotherapy after one treatment cycle because of toxicity (see 'Toxicity' section). This patient was removed from the study and no formal staging was carried out, but the patient was included for calculation of survival by intent-to-treat analysis.
The median OS was 7.7 months and the median PFS 7.7 months (Figure 1 ). Six (43%) patients were alive and in CR at a median of 54.5 months (range 20-72 months). Four of these six patients had an aaIPI of zero or one and two an aaIPI of two. Three of these six patients had stage I or II and three had stage III or IV disease. In two of the six patients, alive in CR 23 and 56 months, respectively, the initial lactate dehydrogenase (LDH) level was above the normal value. In the other four patients, the LDH level at diagnosis was within normal range (data not shown). The OSs according to aaIPI and stage are shown in Figure 2A and B.
The patient with mantle cell lymphoma initially responded with a CR but relapsed early and died 9 months after diagnosis. The patient with grade III follicular lymphoma is alive in CR 23 months after diagnosis. toxicity A total of 48 treatment cycles were evaluable for toxicity ( Table 2) . Neutropenia was the most frequently reported toxicity, with grade 3 or 4 neutropenia in 23% of all treatment cycles. Other grade 3 and 4 hematologic toxic effects were rather low, with leukopenia in 11%, thrombocytopenia in 6%, and anemia in 2% of the total treatment cycles. In 10% of all cycles, grade 3 infections were recorded. Grade 4 infections were not observed. Only two patients received G-CSF as secondary prophylaxis. Non-hematologic grade 4 toxic effects were generally not reported. Grade 3 non-hematologic toxic effects included renal toxicity (4%), fatigue (6%), vertigo (2%), and one psychotic episode (2%). The latter led to removal of the patient from study treatment. This patient was not assessable for response but was included in survival analyses. As in other treatment studies with bendamustine, alopecia was not present. The high frequency of grade 1 renal toxicity was due to preexisting low-grade renal insufficiency in this group of elderly individuals. Treatment-related mortality was not observed.
Besides the patient with the psychotic episode, in whom treatment was terminated before completing the prerequisite cycles, two other patients refused to continue treatment after one and two cycles, respectively. There were no dose reductions; however, treatment was delayed in 8 (57%) patients and in 16 (33%) of all treatment cycles. Treatment delays ranged between 6 and 33 days and were due to patient 
discussion
This report represents the first study with bendamustine in combination with rituximab in aggressive B-cell NHL as well as the first study with bendamustine in the first-line setting in this group of diseases. The rationales for choosing this regimen for elderly patients with aggressive NHL were the feasibility and efficacy of treatment with bendamustine as shown in our own study several years ago [8] , the experience in this study and in other patients that bendamustine at the given dose had been well tolerated even in elderly patients, reports in low-grade lymphoma that rituximab can be added to bendamustine without major increase of toxicity [16] , and our own in vitro studies, which had demonstrated synergism between bendamustine and rituximab in B-cell lymphoma cell lines [12] . Our results clearly demonstrate that the combination of bendamustine and rituximab is active in aggressive B-cell lymphoma, and moreover, as four of the patients are alive without disease 4 years or longer, they indicate that the regimen may be even curative in a proportion of patients. The study was not designed to replace the current standard, R-CHOP, in elderly patients [1] . It was conducted to provide a reasonable treatment modality for patients, who were judged by their treating oncologists, not to qualify for R-CHOP. Indeed, Thieblemont et al. [2] pointed out in their retrospective analysis of NHL patients older than 80 years that a therapeutic decision was often problematic. In their population of 205 patients, only 4% had received standard CHOP or R-CHOP. The rate of toxic death in the total population was 16%. One hundred two of their patients had an aggressive lymphoma. In these, the median survival was 1.2 years, with less than 20% of the patients still alive after 4 years. The rate of complete remissions in this group was 36%. This analysis indicates that in the general population of patients older than 80 years with aggressive lymphomas, many are not judged by their physicians to qualify for CHOP or R-CHOP and therefore alternative and possibly less toxic regimens are needed. However, for this agegroup, there is a paucity of information available to guide the decisions on disease management.
The CR rate of 54% in the present study may be somewhat lower than in a population of patients older than 80 years treated with R-CHOP; however, one has to consider that such a patient group undergoes strong selection and only patients with an excellent performance status and little comorbidity will finally undergo treatment with R-CHOP. As described above, Thieblemont et al. [2] reported that only a small minority of their patients received standard R-CHOP or CHOP. In this respect, currently it is not the question whether R-CHOP or other treatment modalities as R-bendamustine are the most effective treatments in the very elderly population but to select an appropriate modality for an individual patient.
In a study by the Italian 'Non-Hodgkin's Lymphoma Cooperative Study Group' [3] using a regimen consisting of mitoxantrone, etoposide, prednisone, bleomycin, and vincristine, a subgroup of 25 patients older than 80 years was analyzed for efficacy and toxicity. The response rate was comparable with our study, with 68% ORR and 52% CR. Generally, the regimen was well tolerated; however, four patients died during the course of chemotherapy, two of them with documented bacteremia [3] . To our knowledge, this is the only published study besides the results presented here in very old patients with aggressive lymphoma and this paucity of data documents the need for further trials in this age-group. Experience with different regimens and inclusion of geriatric scores are necessary to facilitate the decision, in whom a standard treatment approach may be feasible and in whom alternative regimens may be the better choice. original article
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A subgroup analysis of our study revealed that a benefit of treatment with rituximab and bendamustine was not only present in patients with limited stages or low IPI, three patients with stage III disease and two patients with intermediate-high risk according to IPI were alive in complete remission 20 months or longer after the start of treatment. However, due to the low number of patients, it was not possible to select for any factors that would predict patients with favorable outcomes after treatment with rituximab and bendamustine. In the retrospective analysis by Thieblemont et al. [2] , both IPI and Ann Arbor staging were independent prognostic factors in a multivariate analysis. This is also probably true for patients treated with rituximab and bendamustine; nevertheless, our data suggest that the combination may be curative also in a proportion of patients with advanced-stage and/or unfavorable IPI.
Considering the high age of our patient population, the toxicity of the combination of bendamustine with rituximab was rather low. It was in the range of our previous study with bendamustine monotherapy in relapsed and refractory aggressive lymphomas [8] . Granulocytopenia was somewhat more pronounced in the present study, which may be attributable to the addition of rituximab, which has been described to increase the rate of granulocytopenia in studies with combinations of the antibody with CHOP-like regimens [1, 4, 20] . In comparison with studies using the combination of bendamustine and rituximab [16] [17] [18] in patients with relapsed indolent or mantle cell lymphomas, hematotoxicity and nonhematologic toxic effects were very similar, which confirms the low toxicity of this treatment modality.
However, the toxicity profile of bendamustine and rituximab is a lot more advantageous when compared with combinations of rituximab with CHOP-like therapy [4, 5] . Especially regarding hematotoxicity and infections, the rates were much lower than in elderly patients (60-80 years) who were treated with R-CHOP-14 or R-CHOP-21 [1, 4, 5] . Of note, the low hematotoxicity in the present study was recorded despite only two patients having received G-CSF. Additionally, as described by others [16] [17] [18] , the combination does not lead to hair loss. Because of the generally low toxicity, the combination may be suitable for those patients who do not qualify for R-CHOP. Patients with a low ejection fraction and those with a low performance status were excluded in the present study because it was a feasibility study with a combination of drugs, with which there was no experience at the beginning of the study. However, these patients may be exactly the groups most likely to benefit from bendamustine and rituximab because cardiac toxicity is low, and otherwise, the regimen is well tolerated by very elderly patients as demonstrated by this study.
In conclusion, the combination of bendamustine with rituximab is effective and well tolerated and should therefore be considered especially in very elderly patients with aggressive B-cell lymphomas who do not qualify for R-CHOP. However, the number of patients in the present study is low, and thus, the results need to be confirmed in a study with larger patient numbers. Currently, the German High-Grade Non-Hodgkin Lymphoma Study Group is preparing a large phase II trial with our regimen in patients with a high comorbidity using the same dosages of the two drugs. This trial will include geriatric assessment scores, which may help, together with other factors, to identify patient populations with aggressive B-cell lymphomas who will benefit from therapy with bendamustine and rituximab.
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